(redirected from Toll-like receptor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
See: receiver
Mentioned in ?
References in periodicals archive ?
Messenger RNA (mRNA) levels of toll-like receptor 9 (TLR9) (A), myeloid differentiation primary response 88 (MYD88) (B), interleukin-1 receptor-associated kinase 1 (IRAKI) (C), tumor necrosis factor receptor-associated factor 6 (TRAF6) (D), and nuclear factor B (NF-[kappa]B) (E) in peripheral blood mononuclear cells of chronic hepatitis B virus (CHB)-infected patients with different hepatitis B virus (HBV) DNA viral loads.
Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates and has a clinical development program in autoimmune diseases.
The problem is that if you happen to be an individual who has the 'wrong' genetic code in toll-like receptor 3, you might inadvertently trigger a detrimental effect in your retina," Dr.
Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression ofTLR3 in dendritic cells.
VentiRx continues to advance development of its investigational immuno-oncology agent, motolimod, a novel Toll-like Receptor 8 (TLR8) agonist that directly activates multiple components of the innate immune system.
Toll-like receptors and the innate immune system, critical components of the normal human response to infection, are essential to naturally and experimentally induced autoimmunity.
Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2.
Researchers now report that in certain people, one of these signaling molecules, toll-like receptor 4, is not so trigger-happy.
In contrast, LPS docks to a cell-surface receptor, mCD14, which then complexes with a transmembrane signaling receptor, the toll-like receptor 4 (TLR4) (31).
Idera Pharmaceuticals, (NASDAQ: IDRA) a biotechnology company developing Toll-like receptor candidates for the treatment of autoimmune diseases and for use as vaccine adjuvants, today announced that members of the management team will be presenting at the third annual "Cancer Immunotherapy: A Long-Awaited Reality Conference" at the New York Academy of Medicine in New York City.
Motolimod is a novel Toll-like Receptor 8 (TLR8) agonist that directly activates multiple components of the innate immune system.